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Abstract: A promising approach to facilitate protective mechanical ventilation is the use of extracorporeal CO2 re-
moval techniques. Several strategies based on membrane gas exchangers have been developed. However, these 
techniques are still poorly available. The goal of this study was to assess the efficacy and safety of THAM infusion 
coupled to hemofiltration for the management of hypercapnic acidosis. A severe respiratory acidosis was induced in 
seven anesthetized pigs. Five of them were treated with THAM 8-mmol·kg-1·h-1 coupled to hemofiltration (THAM+HF 
group) at 100 mL·kg-1·h-1. After 18-hours of treatment the THAM infusion was stopped but hemofiltration was kept 
on until 24-hours. The 2 other animals were treated with THAM but without hemofiltration. After 1-hour of treat-
ment in THAM+HF, PaCO2 rapidly decreased from a median of 89.0 (IQR) (80.0, 98.0) to 71.3 (65.8, 82.0) mmHg 
(P<0.05), while pH increased from 7.12 (7.01, 7.15) to 7.29 (7.27, 7.30) (P<0.05). Thereafter PaCO2 remained stable 
between 60-70 mmHg, while pH increased above 7.4. After stopping THAM at 18 hours of treatment a profound 
rebound effect was observed with severe hypercapnic acidosis. The most important side effect we observed was 
hyperosmolality, which reached a maximum of 330 (328, 332) mOsm·kg H2O
-1 at T18. The animals treated only with 
THAM developed severe hypercapnia, despite the fact that pH returned to normal values, and died after 12 hours. 
Control-group had an uneven evolution until the end of the experiment. A combined treatment with THAM coupled 
to hemofiltration may be an effective treatment to control severe hypercapnic acidosis. 
Keywords: Acute respiratory distress syndrome, extracorporeal CO2 removal, hemofiltration, hypercapnia, Tris 
hydroxymethyl aminomethane (THAM), ventilator induced lung injury
Introduction
During the last years there has been an increas-
ing interest for introducing extracorporeal CO2 
removal (ECCO2R) techniques in the manage-
ment of patients with severe respiratory failure 
[1, 2]. One of its major potential roles appears 
to be the possibility of providing more protec-
tive mechanical ventilation (MV) to patients 
with moderate to severe acute respiratory dis-
tress syndrome (ARDS) to avoid ventilator 
induced lung injury [3]. Other source of interest 
derives from patients with decompensate 
chronic obstructive pulmonary disease, who do 
not respond to noninvasive ventilation, and in 
whom there is general reluctance to consider 
intubation [4]. 
The first techniques to provide ECCO2R were 
tested several decades ago, by using conven-
tional circuits for extracorporeal membrane 
oxygenation (ECMO), but at lower blood flows. 
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This technology has remained available for 
decades [5, 6], but its use has been limited by 
several factors, including risks of hemorrhage 
and complex technical requirements similar to 
classical ECMO. More recently, several alterna-
tives of ECCO2R have been developed based on 
smaller double-lumen central venous cathe-
ters, and simpler circuits, which resemble 
those used for continuous renal replacement 
therapies (CRRT) [4-7]. These novel ECCO2R 
systems use lower blood flows in the range of 
0.5 to 1 L min-1, and they are able to remove 
around 50% of CO2 produced by metabolism. 
However, the technology is still poorly available, 
they are rather expensive, they include lung 
membrane gas exchangers, the catheters re- 
quired are larger than those usually applied in 
most intensive care units (ICUs) to provide 
CRRT, and they still require significant anti- 
coagulation. 
Tris hydroxymethyl aminomethane (THAM) is a 
buffer (121 daltons) used in Europe since 1959 
as an alternative to sodium bicarbonate for the 
treatment of acidosis [8]. It has the ability to 
bind protons in equimolar proportion, and its 
pKa is 7.8 at 37°C, which allows a better buffer-
ing capacity at physiologic pH. In addition, in 
contrast to bicarbonate, THAM does not 
increase CO2 content. It is eliminated via glo-
merular filtration [9]. It has been used to treat 
not only metabolic acidosis, but also hypercap-
nic acidosis in critically ill patients [10]. How- 
ever, it has a limited efficacy due to the rela-
tively low dose that can be used due to accu-
mulation. Current maximal dosing recommen-
dations are 2 mmol·kg-1·h-1, and 15 mmol·kg-1 
per day. Nevertheless, this restriction may be 
avoided by increasing THAM clearance through 
hemofiltration, which is frequently used in criti-
cally ill patients. Recently, Russ and co-workers 
tested this concept in a short experimental 
study (only 1 hour) [11]. Healthy anesthetized 
animals were hypoventilated up to a PaCO2 
around 70 mmHg, and then THAM was infused 
at 8.8 mmol·kg-1·h-1, combined with hemofiltra-
tion. Hypercapnia was partially controlled and 
arterial pH was normalized with this strategy. 
The goal of this study was to assess in an 
experimental model the efficacy and safety of a 
high dose THAM infusion coupled to hemofiltra-
tion during 18 hours for the management of 
hypercapnic acidosis induced by hypoven- 
tilation.
Material and methods
Animals and instrumentation
The Institutional Review Board for animal care 
of the Universidad Andres Bello approved the 
study. Guide for the Care and Use of Laboratory 
Animals, 8th Edition, from the National Academy 
of Sciences of the United States of America. 
Pigs (Sus scrofa) of 23 to 33 kg weight were 
used in the study. Animals were fasted for 24 
hours before the experiments, but with free 
access to water. They were premedicated with 
ketamine (Ketostop, Drag Pharma S.A, Chile) 
20 mg·kg-1 and xylazine (Ronpum, Bayer Health 
Care, Germany) 2 mg·kg-1 i.m. After inserting a 
peripheral i.v. line, and injecting fentanyl (Fen- 
tanyl, Laboratorio Biosano, Chile) 30 μg·kg-1 
and atracurium (Tracrium, GlaxoSmithKline, 
UK) 2 mg·kg-1 i.v., pigs were intubated and con-
nected to mechanical ventilation in volume 
control ventilation mode (Savina® 300, Dräger, 
Germany) with positive end expiratory pressure 
(PEEP) of 8 cmH2O, tidal volume (Vt) 12 ml·kg
-1. 
Respiratory rate was adjusted to keep end tidal 
CO2 between 35 and 45 mmHg. Anesthesia 
was maintained with a continuous infusion of 
midazolam (Dormonid, Roche, Switzerland) 2 
mg·ml-1, fentanyl 20 μg·ml-1 and ketamine 20 
mg·ml-1, set at 4 ml·kg-1·h-1 during invasive pro-
cedures, and at 2 ml·kg-1·h-1 thereafter until the 
end of the experiment. Muscle paralysis was 
maintained with atracurium 0.5-0.25 mg· 
kg-1·h-1 throughout all the experiment. A bolus 
of 10 ml·kg-1 of lactated Ringer’s solution (Fre- 
senius Kabi, Germany) was infused after anes-
thesia induction and a continuous infusion was 
kept at 4 ml·kg-1·h-1 during the instrumentation 
period. Thereafter, during the rest of the experi-
ment the infusion was kept at 2 ml·kg-1·h-1. In 
parallel, 10% dextrose solution (Fresenius Kabi, 
Germany) was infused starting at 1 ml·kg-1·h-1, 
and adjusted to keep glucose plasma concen-
tration between 80 and 150 mg·dl-1. The left 
carotid artery and the right and left jugular 
veins were surgically exposed for catheter 
insertion. A pulmonary artery catheter (Edwards 
Lifesciences, USA) was placed through the left 
jugular vein. In the animals treated with hemo-
filtration, a double-lumen 12Fr. dialysis cathe-
ter (Haemocat® Signo, B.Braun, Germany) was 
inserted through the right jugular vein. During 
the experiment, end-tidal CO2 (Dräger Infinity 
Mcable-Maistream CO2, USA), electrocardio-
gram, heart rate, pulse oxygen saturation, inva-
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Figure 1. Experimental design for THAM+HF group. The figure describes the four protocol periods, the timeline, and 
the main events. Experimental setup took 2 to 3 hours, which was followed by baseline measurements. There after 
tidal volume was decreased from 12 to 6 ml·kg-1 and followed by a period of 90 minutes for stabilization of hyper-
capnia. After taking measurements (T0), THAM infusion and hemofiltration were started and maintained for a treat-
ment period of 18 hours (T18). Then THAM infusion was stopped and hemofiltration was kept on for six additional 
hours to assess the post-treatment effects. MV, mechanical ventilation; Vt, tidal volume.
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sive arterial blood pressure, central venous 
pressure, pulmonary artery pressure, pulmo-
nary artery occlusion pressure, cardiac output, 
core temperature (Infinity® Delta XL, Dräger, 
USA) and urine output, were monitored every 
hour.
Experimental design (Figure 1) 
In seven animals we induced hypercapnic aci-
dosis by hypoventilation. Five of them were allo-
cated to be treated with THAM plus hemofiltra-
tion (THAM+HF group), and the other 2 to be 
treated just with THAM, but without hemofiltra-
tion (THAM group). In addition to these seven 
animals, we included five animals as sham 
(Control group). In these 5 control animals we 
kept them anesthetized and with controlled 
ventilation at Vt 12 ml·kg-1 and respiratory rate 
adjusted to maintain PaCO2 between 35 and 
45 mmHg during the 24-hours study period. In 
the seven animals allocated to hypercapnic aci-
dosis, baseline measurements were performed 
after the instrumentation period, and then Vt 
was decreased from 12 to 6 ml·kg-1, keeping 
respiratory rate constant. A 90-min period was 
allowed for stabilization of hypercapnia. There 
after (time 0, T0), in the THAM+HF group, hemo-
filtration was started while THAM 3 Molar (Tris 
36.34% B.Braun, Germany) was infused by pre-
filter at 8 mmol·kg-1·h-1 (treatment period). In 
this group THAM infusion was stopped after 18 
hours (T18), but hemofiltration was kept on 
until T24. The purpose of this final post-treat-
ment period of 6 hours was to assess the rela-
tive effect of THAM infusion on hypercapnic 
acidosis, as well as any potential post-treat-
ment effect. The THAM group received a THAM 
infusion at 8 mmol·kg-1·h-1 through the central 
venous catheter, but without hemofiltration. 
Efficacy was evaluated through arterial blood 
gases (i-STAT, Abbott Point of Care Inc. IL, USA 
[by cartridge CG4+]) which measures directly 
pH, pCO2, pO2, lactate and calculates bicarbon-
ate [12, 13]; while safety was evaluated by 
measuring repeatedly blood glucose and lac-
tate levels (i-STAT, Abbott Point of Care Inc. IL, 
USA), osmolality by freezing point (Fiske® 210, 
Norwood, Massachusetts, USA), phosphatemia 
(Hitachi U-5100 UV-Vis Spectrophotometer), 
free hemoglobin (spectrophotometer assays 
based on a peroxidase reaction, Hitachi U-5100 
UV-Vis Spectrophotometer), as well as systemic 
hemodynamics, temperature and vital signs. 
Each experiment ended with euthanasia of the 
pig.
Setup of hemofiltration
Hemofiltration was performed using a continu-
ous renal replacement therapy machine 
(Diapac Acute, B.Braun, Germany) with a poly-
sulfone filter (2-m2 surface area, inner diameter 
of capillaries 200 μm, wall thickness 40 μm, 
ultrafiltration coefficient 58 mL·h-1·mmHg-1 and 
priming volume bloodside 121 ml [Diacap HI-PS 
20 filter, B.Braun, Germany]). Blood flow was 
fixed at 200 ml·min-1. Lactated Ringer’s solu-
tion (Fresenius Kabi, Germany) was infused 
prefilter (predilution) as replacement fluid at 
100 mL·kg-1·h-1. Hemofiltration was always iso-
volumetric. THAM 3 molar was infused prefilter 
within the circuit at 8 mmol·kg-1·h-1 proximal to 
the replacement fluid. Unfractioned heparin 
(Heparin sodium 5000 UI·ml-1, Fresenius Kabi) 
was infused prefilter and titrated to achieve an 
Figure 2. Respiratory and acid-base variables. Data of arterial partial pressure of carbon dioxide (A), arterial pH (B), 
arterial bicarbonate (C), ventilation (D), and PaO2/FiO2 ratio (E) for Control, THAM+HF, and THAM groups. Vertical 
broken lines at T0 and T18 indicate the start and the end of THAM infusion, respectively. Results are presented as 
median and interquartile range. *P<0.05 compared to baseline (only up to T18); #P<0.05 compared to T0 (only 
up to T18); **P<0.05 for T21 and T24 compared to T18; $P<0.05 for THAM+HF compared to control group. BL, 
baseline (just before decreasing tidal volume from 12 to 6 ml·kg-1). No statistics were performed for THAM group, as 
only two animals were included.
Figure 3. Extracorporeal CO2 removal by THAM cou-
pled with hemofiltration. Vertical broken line at T18 
indicate the end of THAM infusion. Results are pre-
sented as median and interquartile range. *P<0.05 
compared to T1 (only up to T18); #P<0.05 for T24 
compared to T18. 
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activated partial thromboplastin time in the out 
of extracorporeal circuit of 60-80 seconds.
Statistical analysis
Data are presented as median and interquar-
tile range (IQR). Comparisons of continuous 
variables between the two groups were con-
ducted with Mann-Whitney U test. Comparisons 
of different time points within a single group 
were performed by analysis of variance or by 
Friedman test, followed by post-hoc Bonferroni’s 
or Dunn’s test, as appropriate. P<0.05 was con-
sidered as statistically significant. Data were 
analyzed with STATA version 12.0 (StataCorp 
LP, College Station, TX).
Results
Acid-base variables
In the control group, PaCO2, pH and bicarbon-
ate levels remained rather normal and stable 
throughout the experiment (Figure 2). In groups 
Figure 4. Hemodynamics variables. Data of mean arterial pressure (A), heart rate (B), mean pulmonary arterial 
pressure (C), cardiac output (D), and pulmonary arterial occlusion pressure (E) for Control, THAM+HF, and THAM 
groups. Vertical broken lines at T0 and T18 indicate the start and the end of THAM infusion, respectively. Results are 
presented as median and interquartile range. *P<0.05 compared to baseline (only up to T18); #P<0.05 compared 
to T0 (only up to T18); **P<0.05 for T21 and T24 compared to T18; $p<0.05 for THAM+HF compared to control 
group. BL, baseline (just before decreasing tidal volume from 12 to 6 ml·kg-1). No statistics were performed for THAM 
group, as only two animals were included.
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THAM+HF and THAM, after decreasing Vt to 6 
ml·kg-1, PaCO2 rapidly and progressively in- 
creased while pH decreased during the 90 min 
stabilization period. At T0 hypercapnic acidosis 
was still worsening with PaCO2 and pH at 89.0 
(80.0, 98.0) mmHg and 7.12 (7.01, 7.15) in the 
THAM+HF group, and 91.0 (90.4, 91.5) mmHg 
and 7.20 (7.20, 7.22) in the THAM group, 
respectively. 
In the THAM+HF group a few minutes after 
starting treatment, end tidal CO2 stopped 
increasing, and rapidly decreased towards a 
lower level. At time T1 PaCO2 had already 
decreased to 71.3 (65.8, 82.0) mmHg, while 
pH had increased to 7.29 (7.27, 7.30). In the 
following hours of treatment PaCO2 remained 
rather stable but pH continued increasing up to 
T9, after which it remained stable at rather nor-
mal levels, until T18, when THAM infusion was 
stopped. There after, hypercapnic acidosis 
reappeared rapidly within the following hours 
with PaCO2 at 113.4 (93.4, 132.0) mmHg and 
pH at 7.04 (6.93, 7.16) at the end of the experi-
ment at T24. Bicarbonate concentrations in 
plasma increased up to 40 to 50 mmol·L-1 show-
ing a parallel trend to that of pH (Figure 2C). In 
the THAM group PaCO2 and pH rapidly improved 
at T1, but thereafter PaCO2 started to increase 
again rapidly going over 100 mmHg after T3, 
with both animals dying at T12 (Figure 2). 
Bicarbonate increased progressively since the 
start of THAM infusion reaching 76.3 (75.6, 
76.9) mmol·L-1 at T6. In contrast, pH remained 
within rather normal values until the end.
Extracorporeal CO2 removal through hemofiltra-
tion ranged 35 to 45 ml·min-1 (Figure 3), which 
represented 35 to 40% of total CO2 pro- 
duction.
Systemic hemodynamic variables
There were no relevant hemodynamic changes 
along time in the control group (Figure 4). 
Induction of hypercapnic acidosis in groups 
THAM+HF and THAM were associated to tachy-
cardia, pulmonary hypertension, and in- 
creased cardiac output. In the THAM group 
there was a transient decrease in tachycardia 
and pulmonary hypertension after starting 
THAM infusion, but cardiac output continued 
decreasing until both animals died. In the 
THAM+HF group, heart rate, pulmonary arterial 
pressure and cardiac output rapidly normalized 
after starting treatment and kept within normal 
ranges until THAM infusion was stopped at 
T18. Thereafter, pulmonary hypertension, se- 
vere hypotension, and tachycardia, became evi-
dent again (Figure 4).
Safety data
The most important side effect in the THAM+HF 
group was hyperosmolality (Figure 5). 
Osmolality increased significantly after T6 and 
reached a maximum of 330 (328, 332) mO- 
sm·kg H2O
-1 at T18, decreasing towards normal 
values after stopping THAM infusion. Creatine 
kinase increased steadily in the 3 groups even 
after stopping THAM infusion (Table 1). In the 
THAM group, osmolality and creatine kinase 
rose even more rapidly and steadily reaching a 
maximum of 411 (398, 425) mOsm·kg H2O
-1 
and 5343 (1887, 8799) U·L-1, respectively. In 
addition, there was mild hyponatremia in the 
THAM+HF group. Phosphatemia was lower in 
the THAM+HF group compared to the control 
group, but within normal values. Plasma free 
hemoglobin increased only in the THAM group. 
Concerning hematologic variables, the only 
alteration was a drop in the platelets, however 
these were similar in the three study groups 
(Table S1). There was no hypoglycemia and the 
glucose requirements were similar among the 
three groups (dextrose infusion was 1.5 (1.4, 
1.5), 1.7 (1.5, 1.7) and 1.6 (1.5, 1.8) mg·kg-
1·min-1 in THAM+HF, Control and THAM groups, 
respectively; P = 0.2). 
Figure 5. Evolution of the osmolality. Vertical bro-
ken lines at T0 and T18 indicate the start and the 
end of THAM infusion, respectively. Results are pre-
sented as median and interquartile range. *P<0.05 
compared to baseline (only up to T18); #P<0.05 
compared to T0 (only up to T18); **P<0.05 for T21 
and T24 compared to T18; $p<0.05 for THAM+HF 
compared to control group. BL, baseline (just before 
decreasing tidal volume from 12 to 6 ml·kg-1). No sta-
tistics were performed for THAM group, as only two 
animals were included.
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In the THAM+HF group there was a rise in lac-
tate levels during the treatment period which 
reached a peak of 4.1 (3.1, 6.3) mmol·L-1 at 
T18, and which further increased in the post-
treatment period (Table 1). In the THAM group 
there was an early and severe hyperlacta- 
temia.
Discussion
The main finding of this experimental study is 
that THAM coupled to hemofiltration appears to 
be an effective treatment to revert hypercapnic 
acidosis secondary to prolonged hypoventila-
tion. This novel therapeutic approach appears 
to be safe in general, and the main side effect 
was hyperosmolality, which appears to be due 
to THAM accumulation. 
The use of THAM without CRRT in the treatment 
of acidosis is well established [9]. It has even 
been used in the treatment of hypercapnic aci-
dosis in patients with acute lung injury, ARDS 
[10] and severe asthmatic crisis at doses up to 
2 mmol·kg-1·h-1 [14]. It has also been used to 
induce short periods of apnea for bronchosco-
py procedures. In a recent experimental study 
six pigs were subjected to complete apnea for 
up to 4 hours while treated with THAM, but a 
huge dose of 20 mmol·kg-1·h-1 [15]. Four of them 
survived until the end of the experiment keep-
ing pH at a physiologically acceptable level. In 
critically ill patients prolonged infusions as long 
as 5 days of low doses (2 mmol·kg-1·h-1) of THAM 
have been reported, without evident adverse 
events [16]. 
Dialysis and hemofiltration without the use of 
bicarbonate solutions have the ability to clear 
CO2 through bicarbonate removal [17]. However, 
this effect is limited because of the inability to 
maintain electrolyte concentrations and pH 
while removing bicarbonate. Numerous ap- 
proaches to replace bicarbonate have been 
attempted using sodium hydroxide, THAM, and 
other organic anions. However, these attempts 
have failed when applied for extended use 
Table 1. General blood biochemistry
Group T0 T6 T12 T18 T24
Sodium (mmol L-1) 
[136-146]
THAM+HF 136 (134, 137) 132 (131, 133)$ 130 (130, 133)#,$ 131 (128, 134)#,$ 132 (131, 137)$
Control 140 (139, 142) 139 (135, 141) 141 (139, 141) 140 (140, 141) 141 (139, 143)
THAM 135 (134, 135) 134 (133, 135) 125 (124, 125)
Potasium (mmol L-1) 
[3.5-4.9]
THAM+HF 4.1 (4, 4.2) 3.9 (3.9, 4) 4.3 (4.1, 5.2) 5.1 (4.1, 5.5)# 4.7 (3.8, 5.5)$
Control 3.7 (3.4, 3.9) 4.2 (4.1, 4.5)# 4.3 (3.9, 4.4)# 4.2 (3.9, 4.9)# 3.9 (3.6, 4.2)
THAM 4.5 (4.4, 4.6) 4.2 (3.8, 4.6) 5.8 (5.5, 6.1)
Chloride (mmol L-1) 
[98-109]
THAM+HF 98 (94, 100) 97 (94, 98) 102 (99, 103) 100 (100, 105) 104 (103, 106)
Control 96 (95, 97) 98 (98, 99) 98 (97, 103) 101 (98, 103) 100 (98, 102)
THAM 97 (95, 98) 94 (93, 95) 90 (88, 93)
Phosphate (mg dL-1) 
[2.6-4.5]
THAM+HF 7 (6, 7.4) 4.9 (4.9, 5.8)#,$ 3.7 (3.6, 4)#,$ 3.7 (3, 4.2)#,$ 5.4 (4.9, 5.6)**,$
Control 7.4 (6.9, 8) 6.5 (5.4, 7.6) 8.3 (6.8, 8.9) 7.4 (5.6, 10.7) 8.2 (7.5, 9.4)
THAM 8 (7.7, 9) 9 (8.5, 9.6) 6.8 (4.9, 8.7)
Creatinine (mg dL-1) 
[0.6-1.3]
THAM+HF 0.90 (0.6, 1.1) 0.68 (0.59, 0.86)#,$ 0.9 (0.7, 1)$ 0.96 (0.77, 1.07)$ 1.1 (1.08, 1.26)
Control 0.94 (0.7, 1.1) 1.04 (0.8, 1.1) 1.2 (1.1, 1.3) 1.3 (1.2, 1.5)# 1.3 (1, 1.5)
THAM 1 (0.95, 1.06) 1.5 (1.3, 1.7) 2.1 (1.9, 2.3)
Blood urea nitrogen  
(mg dL-1) [8-26]
THAM+HF 8 (5, 8.4) 7 (6.7, 8)$ 5.5 (5, 7)$ 8 (6, 8)$ 8 (7, 9)$
Control 9 (7, 10) 13 (9, 13) 18 (14, 22)# 16 (12, 26)# 18 (13, 29)
THAM 9 (8, 10) 13 (8, 15) 16 (13, 18)
Creatine Kinase  
(U L-1) [38-174]
THAM+HF 554 (359, 771)$ 1632 (983, 2273)# 2265 (1213, 4405)# 3614 (1912, 6040)# 4903 (2622, 7236)$
Control 853 (430, 1722) 2371 (1111, 3631)# 2239 (1132, 6548)# 2455 (1178, 10421)# 2391 (1439, 10628)
THAM 1069 (534, 1604) 3790 (1571, 6009) 5343 (1887, 8799)
Plasma Free Hemo- 
globin (mg dL-1) [0-10.6]
THAM+HF 3.6 (3, 7.1)$ 3.8 (3, 6)$ 5 (4.5, 9)$ 3.2 (2.6, 13)$ 8.3 (6, 11)**
Control 8.5 (5.2, 11) 7.8 (5.9, 9.9) 2.3 (2, 2.6) 7.4 (2.8, 11.9) 6.5 (2, 11)
THAM 2.4 (2, 2.7) 11.4 (2, 20.8) 31.2 (22.5, 40)
Arterial Lactate  
(mmol L-1) [0.36-1.25]
THAM+HF 1.9 (1.3, 2.2) 2.7 (1.7, 4.9)$ 2.7 (2.3, 5.1)$ 4.1 (3.1, 6.3)#,$ 5.2 (2.1, 8.3)**,$
Control 1.5 (0.9, 2) 1.8 (0.8, 2.8) 1.9 (0.8, 2.8) 1.2 (0.6, 2.1) 1.1 (0.6, 1.8)
THAM 1.2 (0.3, 2.1) 3.9 (2, 4.1) 10.6 (7.4, 13.8)
In the first column each parameter is shown with its corresponding units () and normal range []. Results are presented as median and interquartile range. #P<0.05 com-
pared to T0 (only up to T18); **P<0.05 for T24 compared to T18; $P<0.05 for THAM+HF compared to control group. No statistics were performed for THAM group, as only 
two animals were included.
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because of fluid gain, hyperchloremic acidosis, 
hemolysis, cardiac arrhythmias and acid-base 
disorders [17-19]. In this study, by combining a 
high dose infusion of THAM coupled to hemofil-
tration, we were able to overcome most of 
these limitations and could treat effectively a 
severe hypercapnic acidosis for at least 18 
hours.
The rationale of this strategy is that THAM cap-
tures protons favoring the dissociation of car-
bonic acid into bicarbonate, decreasing PaCO2 
and increasing bicarbonate and base excess. 
Although protonated THAM and bicarbonate 
can then be excreted by urine, this occurs at a 
rather low rate, which limits the maximal effi-
cacy of the strategy and its time extension. 
However, if hemofiltration is added, the dose of 
THAM can be increased leading to more excre-
tion of THAM, protons and bicarbonate, besides 
allowing for a longer treatment. 
In a recent experimental study in which severe 
respiratory acidosis was induced in pigs, 
Karagiannidis and co-workers [20] observed 
that when using lung membrane oxygenators, 
blood flows over 750 ml·min-1 were required to 
restore a normal pH. In the present study pH 
was effectively corrected with an extracorpore-
al blood flow of only 200 ml·min-1, which corre-
sponded to 5.2 (4.7, 8.4)% of cardiac output. 
Although acidosis was fully corrected by 
THAM+HF, as reflected by pH which increased 
over 7.4, hypercapnia was only partially revert-
ed. Bicarbonate increased slowly but progres-
sively, in parallel to osmolality, during the 18 
hours of THAM infusion. This increase in bicar-
bonate level had already been described in a 
previous study using a high dose of THAM [15], 
but reaching markedly higher levels than those 
observed in our study in the THAM+HF group. 
While protons may be removed bound to THAM, 
or buffered by increasing concentrations of 
THAM, CO2 removal remains dependent on 
bicarbonate elimination. The increasing con-
centrations of bicarbonate as well as progres-
sive hyperosmolality, which suggest THAM 
accumulation, indicate that the dose of THAM 
relative to hemofiltration rate was perhaps still 
too high. However, when comparing it to the lev-
els observed in the THAM group (without HF), it 
becomes evident that hemofiltration had a sub-
stantial contribution to the buffering efficacy of 
THAM (by removing most of the protonated 
THAM and bicarbonate generated).
Other factors related to hemofiltration may 
have increased the alkalinizing effect of the 
treatment. Lactate present in the replacement 
fluid can be metabolized generating bicarbon-
ate [21]. Removal of unmeasured anions by 
hemofiltration may have also contributed to 
this effect [22].
The use of THAM and hemofiltration appears to 
have several potential advantages compared to 
conventional ECCO2R techniques based on 
lung membranes. First, renal replacement equi- 
pment to provide hemofiltration is widely avail-
able worldwide [23]. On the other hand, THAM 
is a commercially available buffer already used 
in clinical practice [9]. Second, the technique 
proposed is relatively inexpensive. Third, it can 
be applied through conventional dialysis cath-
eters. Forth, it requires less anticoagulation. 
Fifth, hemofiltration has the ability to remove 
not only CO2, but also other molecules, and flu-
ids. Besides, because lung edema plays a 
major role in ARDS, the possibility of inducing 
negative fluid balance is highly relevant. How- 
ever, other forms of renal replacement therapy 
such as dialysis or hemodiafiltration with used 
of bicarbonate-free solutions, may also poten-
tially work to enhance THAM removal. This 
alternative should be assessed in the future.
Concerning safety, the main side effects previ-
ously reported for THAM were hypoglycemia 
and hyperkalemia [9]. We observed no hypogly-
cemia and although glucose at low dose was 
infused regularly to keep normal glucose levels, 
there was no difference between groups in the 
amount of glucose infused. Potassium in- 
creased moderately in the THAM group but not 
in the THAM+HF group. The main side effect 
that we identified was hyperosmolality, which 
was progressive and reached a peak level 
around 330 mOsm·kg H2O
-1 at time T18 in the 
THAM+HF group, but more than 400 mOsm·kg 
H2O
-1 in the THAM group already at T12. 
Elevated blood lactate concentrations in 
THAM+HF group were probably related to the 
use of a lactate based solution as fluid replace-
ment for hemofiltration, as has been reported 
previously [24]. In fact, after stopping THAM 
infusion at T18, the concentration of lactate 
continued to rise. A different situation may 
have occurred in the THAM group, where lac-
tate levels at T12 were greater than 10 mmol·L-1, 
probably reflecting a situation of systemic toxic-
ity, secondary to accumulation of THAM.
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We think that hyperosmolality reflects both, 
bicarbonate and THAM accumulation. Although 
in this study we used a fix and rather high THAM 
dose, accumulation could be potentially pre-
vented in the future by increasing the hemofil-
tration rate. We acknowledge several limita-
tions of our study. First, we included only two 
animals in the THAM group. Our purpose with 
this group was just to make evident that hemo-
filtration played a major role in the efficacy of 
the strategy. After treating these 2 animals with 
THAM without hemofiltration, and observing 
how early they died after severe hemodynamic 
instability, it was neither ethical nor necessary 
to include more animals in this group. Second, 
we tested the strategy in animals without acute 
lung injury. Our goal was just to validate the 
concept and feasibility. However, we cannot 
extrapolate our results obtained in these ani-
mals intentionally hypoventilated, to conditions 
of acute respiratory failure where such a strat-
egy appears as an attractive alternative to 
avoid ventilator-induced lung injury. Third, the 
doses of THAM and hemofiltration rate used 
were probably not optimal, as we did not per-
form a dose-response curve. 
In conclusion, this experimental study shows 
that a combined treatment with THAM and 
hemofiltration may be an effective alternative 
to control severe hypercapnic acidosis for at 
least 18 hours. The main side effect was serum 
hyperosmolality.
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Table S1. Hematologic, hepatic and biochemical laboratory data
Variable Group T0 T6 T12 T18 T24
Hemoglobin  
(gr·dL-1) [7.1-12]
THAM+HF 7.4 (7.3, 8.3) 8.3 (7.6, 8.9) 8.1 (7, 8.5) 8.5 (6.8, 8.7) 7.5 (5.7, 9.3)
Control 7.3 (6.8, 7.7) 8.4 (7.3, 9) 8.6 (7.6, 8.8) 8.2 (7.2, 8.4) 8.1 (7.7, 8.9)
THAM 8.4 ( 8.2, 8.5) 9.8 (8.8, 10.7) 12.4 (11.7, 13)
White blood cells  
(x 103/μL) [4.5-11]
THAM+HF 11.4 (11.1, 11.6) N/A 11.9 (11.4, 11.8) 11.8 (11.7, 12.2) 12.5 (11.3, 13.8)**
Control 11.6 (11.5 , 11.8) N/A 11.8 (11.7, 11.9) 12.7 (12, 13.3) 11.7 (11.4, 11.9)
THAM 12 (11.9, 12.2) N/A 11.1 (10.9, 11.3)
Platelet count  
(x 103/μL) [150-400]
THAM+HF 403 (381, 424) N/A 202 (149, 257)# 191 (152, 217)# 169 (124, 189)
Control 367 (340, 390) N/A 172 (165, 179)# 160 (153, 166)# 159 (144, 174)
THAM 340 (323, 358) N/A 222 (186, 259)
Alanine transaminase  
(U·L-1) [10-40]
THAM+HF 37 (27, 42) N/A 40 (28, 45) 52 (37, 61) 60 (30, 121)$
Control 45 (42, 66) N/A 42 (41, 66) 38 (34, 72) 38 (27, 66)
THAM 45 (39, 51) N/A 27 (13, 41)
Aspartate aminotrans-
ferase  
(U·L-1) [10-55]
THAM+HF 17 (16, 20)$ N/A 68 (66, 121)# 495 (438, 750)#,$ 1369 (1312, 4160)**,$
Control 34.5 (27, 59) N/A 58 (42, 87) 40 (31, 121) 63.5 (47, 102)
THAM 32 (29, 34) N/A 171 (116, 225)
Alkaline phosphatase  
(U·L-1) [45-115]
THAM+HF 115 (96, 132) N/A 272 (144, 307)#,$ 536 (260, 574)#,$ 616 (407, 630)$
Control 81 (67, 95) N/A 91 (70, 137) 51 (40, 126) 109 (91, 130)
THAM 100 (88, 112) N/A 197 (184, 209)
Total Bilirubin  
(mg·dL-1) [0-1]
THAM+HF 0.06 (.04, 0.09)$ N/A 0.08 (0.07, 0.1)$ 0.27 (0.1, 0.66)#,$ 0.8 (0.57, 1.4)**,$
Control 0.13 (0.1, 0.15) N/A 0.15 (0.1, 0.15) 0.1 (0.05, 0.15) 0.15 (0.1, 0.15)
THAM 0.06 (0.03, 0.08) N/A 0.08 (0.05, 0.1)
Indirect Bilirubin  
(mg·dL-1) [≤ 0.3]
THAM+HF 0.04 (0.04, 0.05) N/A 0.08 (0.05, 0.13) 0.17 (0.09, 0.34)#,$ 0.68 (0.53, 1.05)**,$
Control 0.06 (0.04, 0.09) N/A 0.05 (0.04, 0.08) 0.04 (0.03, 0.09) 0.05 (0.04, 0.09)
THAM 0.05 (0.02, 0.07) N/A 0.09 (0.08, 0.09)
Gamma-glutamyl tran- 
sferase (U·L-1) [4-50]
THAM+HF 28 (26, 29) N/A 22 ( 21, 28) 27 (24, 32) 44 (31, 52)**
Control 36 (22, 46) N/A 38 (20, 41) 35 (32, 51) 33 (21, 40)
THAM 36 (33, 39) N/A 42 (38, 46)
Prothrombin time  
(sec) [2-8]
THAM+HF 11 (10.7, 11.2) N/A 12.5 (11.5, 13.7) 11.3 (10.5, 14) 24.3 (22.1, 31)**,$
Control 10.2 (10, 10.3) N/A 10.2 (9.3, 11.1) 11 (10.6, 11.3) 11.3 (10.6, 12)
THAM 10.8 (10.6, 10.9) N/A 10.5 (10.3, 10.6)
Lactate dehydrogenase  
(U·L-1) [135-225]
THAM+HF 318 (298, 339)$ N/A 397 (348, 788)# 744 (544, 1146)# 1936 (1365, 2722)**,$
Control 396 (352, 577) N/A 466 (346, 661) 545 (395, 672)# 876 (450, 970)**
THAM 455 (423, 487) N/A 837 (783, 890)
iCa++(mmeq·L-1)  
[2.2-2.6]
THAM+HF 2.7 (2.6, 2.7) 2.5 (2.3, 2.5) 2.6 (2.5, 2.6) 2.6 (2.5, 2.6) 2.9 (2.6, 2.9)$
Control 2.6 (2.5, 2.6) 2.4 (2.3, 2.5) 2.6 (2.5, 2.6) 2.5 ( 2.3, 2.5) 2.2 (2.1, 2.4)
THAM 2.6 (2.5, 2.6) 1.8 (1.7, 1.9) 1.3 (1.2, 1.3)
Proteins (gr·dL-1)  
[5.5-8.0]
THAM+HF 4.1 (3.5, 4.2) N/A 4.2 (3.1, 4.4) 3.9 (3.3, 4.3) 2.8 (2, 3.6)$**
Control 4.1 (4, 4.1) N/A 4 (3.8, 4.3) 4.1 (3.8, 4.5) 3.8 (3.5, 4)
THAM 4.9 (4.8, 5.1) N/A 5.4 (5.1, 5.7)
Albumine (gr·dL-1)  
[3.5-5.0]
THAM+HF  2.1 (1.9, 2.2) 2 (2, 2.1) 2.1 (2, 2.3) 2.1 (1.9, 2.5) 1.6 (1.5, 2.3)
Control 2 (1.9, 2.1) 2.2 (1.9, 2.4) 1.9 (1.8, 1.9) 1.8 (1.7, 2) 1.8 (1.7, 1.9)
THAM 2.4 (2, 2.9) 2.7 (2.5, 2.9) 2.6 (2.2, 2.9)
In the first column each parameter is shown with its corresponding units () and normal range []. Results are presented as median and interquartile range. #p<0.05 
compared to T0 (only up to T18); **p<0.05 for T24 compared to T18; $p<0.05 for THAM+HF compared to control group. No statistics were performed for THAM group, 
as only two animals were included. N/A, not assessed. 
